S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Laser breakthrough could send stock soaring 2,467% (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Laser breakthrough could send stock soaring 2,467% (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Laser breakthrough could send stock soaring 2,467% (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Laser breakthrough could send stock soaring 2,467% (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Laser breakthrough could send stock soaring 2,467% (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Laser breakthrough could send stock soaring 2,467% (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
S&P 500   4,274.51
DOW   33,550.27
QQQ   355.04
Cintas: A Quality Buy and Hold Forever Stock at Any Price
Laser breakthrough could send stock soaring 2,467% (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
Laser breakthrough could send stock soaring 2,467% (Ad)
The Odds Are High Costco Will Declare a Special Dividend Soon 
This Little Known Automaker May Save Your Life and Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
How You Can Reverse Engineer Michael Burry's Latest Buy
Target Will Close 9 Stores Across 4 States Due to Ongoing Crime That's 'Threatening the Safety' of Customers and Employees
NASDAQ:CTMX

CytomX Therapeutics (CTMX) Stock Forecast, Price & News

$1.27
+0.01 (+0.79%)
(As of 09/27/2023 ET)
Compare
Today's Range
$1.26
$1.29
50-Day Range
$1.26
$1.82
52-Week Range
$1.17
$3.02
Volume
88,024 shs
Average Volume
1.12 million shs
Market Capitalization
$84.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.40

CytomX Therapeutics MarketRank™ Forecast

Analyst Rating
Reduce
1.75 Rating Score
Upside/​Downside
88.7% Upside
$2.40 Price Target
Short Interest
Bearish
3.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
-0.24mentions of CytomX Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$31,468 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.37) to ($0.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

808th out of 976 stocks

Pharmaceutical Preparations Industry

376th out of 453 stocks


CTMX stock logo

About CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Astellas Pharma Inc., ModernaTX, Inc., and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in South San Francisco, California.

CTMX Price History

CTMX Stock News Headlines

CytomX Therapeutics (NASDAQ: CTMX)
Something is Coming for America's Top Stock
This stock has already doubled this year - but it could hurt your portfolio if you hold it much longer. Learn why here.
H.C. Wainwright Keeps Their Hold Rating on CytomX Therapeutics (CTMX)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Barclays Remains a Buy on CytomX Therapeutics (CTMX)
Earnings Preview For CytomX Therapeutics
CytomX Therapeutics (CTMX) Gets a Hold from Mizuho Securities
Q1 2023 CytomX Therapeutics Inc Earnings Call
CytomX Therapeutics (CTMX) Receives a Hold from Mizuho Securities
See More Headlines
Receive CTMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CTMX Company Calendar

Last Earnings
8/08/2023
Today
9/28/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CTMX
Employees
116
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.40
High Stock Price Forecast
$3.19
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+88.7%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

Net Income
$-99,320,000.00
Pretax Margin
-63.92%

Debt

Sales & Book Value

Annual Sales
$53.16 million
Book Value
($1.30) per share

Miscellaneous

Free Float
62,161,000
Market Cap
$84.80 million
Optionable
Optionable
Beta
0.65
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Sean A. McCarthy D.Phil. (Age 56)
    DPHIL, Chairman & CEO
    Comp: $1.03M
  • Mr. Lloyd A. Rowland Jr. (Age 66)
    J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec.
    Comp: $608.72k
  • Mr. Jeffrey Landau B.S. (Age 45)
    M.B.A., Sr. VP, Head of Strategy & Chief Bus. Officer
    Comp: $581.68k
  • Mr. Christopher W. Ogden (Age 39)
    Sr. VP of Fin. and Accounting, Principal Financial Officer & Principal Accounting Officer
  • Dr. Marcia P. Belvin Ph.D.
    Sr. VP & Chief Scientific Officer
  • Dr. Chau Cheng M.B.A.
    Ph.D., VP of Investor Relations & Corp. Communications
  • Ms. Danielle Olander-Moghadassian
    Sr. VP & Chief HR Officer
  • Ms. Leslie Robbins
    Sr. VP of Intellectual Property
  • Dr. Yu-Waye Chu M.D. (Age 55)
    Chief Medical Officer
  • Ms. Dawn Benson
    Sr. VP of Quality & Product Manufacturing













CTMX Stock - Frequently Asked Questions

Should I buy or sell CytomX Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" CTMX shares.
View CTMX analyst ratings
or view top-rated stocks.

What is CytomX Therapeutics' stock price forecast for 2023?

4 brokerages have issued 12 month price targets for CytomX Therapeutics' shares. Their CTMX share price forecasts range from $2.00 to $3.19. On average, they predict the company's stock price to reach $2.40 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price.
View analysts price targets for CTMX
or view top-rated stocks among Wall Street analysts.

How have CTMX shares performed in 2023?

CytomX Therapeutics' stock was trading at $1.60 on January 1st, 2023. Since then, CTMX shares have decreased by 20.6% and is now trading at $1.27.
View the best growth stocks for 2023 here
.

When is CytomX Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our CTMX earnings forecast
.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.17. The biotechnology company earned $24.72 million during the quarter, compared to the consensus estimate of $17.38 million. CytomX Therapeutics had a negative net margin of 84.21% and a negative trailing twelve-month return on equity of 666.28%.

What ETF holds CytomX Therapeutics' stock ?

Formidable ETF holds 318,111 shares of CTMX stock, representing 1.80% of its portfolio.

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend.

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.72%), Renaissance Technologies LLC (1.68%), Bronte Capital Management Pty Ltd. (1.39%), Marshall Wace LLP (1.01%), Congress Park Capital LLC (0.16%) and LPL Financial LLC (0.15%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland, Marcia Belvin and Sean A Mccarthy.
View institutional ownership trends
.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $1.27.

How much money does CytomX Therapeutics make?

CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $84.80 million and generates $53.16 million in revenue each year. The biotechnology company earns $-99,320,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

The company employs 116 workers across the globe.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353.

This page (NASDAQ:CTMX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -